CRDF - Cardiff Oncology Announces Positive Onvansertib Monotherapy Clinical Data

2023-09-27 07:42:23 ET

(24/7 MARKET NEWS) – Cardiff Oncology, Inc. (NASDAQ: CRDF) reported, after yesterday’s market close, positive clinical data with onvansertib monotherapy and combination therapy in our ongoing trials in metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC), as well as plans for a mPDAC first-line investigator-initiated trial (IIT) of the combination of onvansertib plus standard-of-care (SoC).

Cardiff Oncology is trading at $1.88, up $0.260 (+16.05%), on 4.35M premarket shares traded.

Its 52-week range is $1.20 to $2.79. Its next key inflection point is $2 and it’s already traded above that this morning when it hit this morning’s $2.34 high.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the …

The post Cardiff Oncology Announces Positive Onvansertib Monotherapy Clinical Data appeared first on 24/7 Market News .

For further details see: